Early Identification of Disease Progression in ALK-Rearranged Lung Cancer Using Circulating Tumor DNA Analysis

Investigators utilized 343 longitudinal plasma DNA samples from 43 ALK alterations NSCLC patients receiving ALK-directed therapies to determine molecular progression based on matched panel-based targeted next-generation sequencing, and shallow whole-genome sequencing.